Tatyana Feldman, MD
Medical Oncology · Hackensack, NJNPI 1578528089
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Seagen Inc. at 34.2% of the total. Reporting peaked in 2023 at $47,276 and has fallen 58.7% since, to $19,526 in 2025. Among medical oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1073.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$66K
- AbbVie$40K
- Takeda$15K
- Genmab U.S., Inc.$13K
- AstraZeneca$11K
- Bristol Myers Squibb$10K
- plus $39K from 16 others
Across 503 payments — averaging $16,285 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$2.5M
- Genmab U.S., Inc.$1.7M
- Daiichi Sankyo Inc.$1M
- Bristol Myers Squibb$971K
- Pfizer$919K
- E.r. Squibb & Sons, L.L.C.$367K
- plus $657K from 9 others
What the payments were for
- Consulting fees$63,54633%
- Speaking & faculty fees$113,40259%
- Travel & lodging$10,6756%
- Food & beverage$5,3743%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 52 | $66,102 |
| AbbVie | 34 | $39,752 |
| Takeda | 3 | $14,886 |
| Genmab U.S., Inc. | 12 | $12,713 |
| AstraZeneca | 18 | $10,941 |
| Bristol Myers Squibb | 16 | $9,802 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $7,934 |
| Gilead(2 entities) | 10 | $7,566 |
| E.r. Squibb & Sons, L.L.C. | 2 | $7,266 |
| ADC Therapeutics America, Inc. | 1 | $3,500 |
| Ipsen Biopharmaceuticals, Inc | 3 | $2,855 |
| Kyowa Kirin, Inc. | 3 | $2,471 |
| Karyopharm Therapeutics Inc. | 1 | $1,938 |
| Pfizer | 4 | $1,857 |
| Daiichi Sankyo Inc. | 1 | $1,645 |
| Epizyme, Inc. | 1 | $1,250 |
| Johnson & Johnson | 2 | $243 |
| Secura Bio, Inc. | 1 | $152 |
| Genentech USA, Inc. | 5 | $119 |
| Regeneron | 1 | $70 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $65 |
| Merck | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,156 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 173 | $2,576,860 |
| CalquenceAcalabrutinib Maleate | 114 | $1,733,723 |
| VenclextaVenetoclax | 56 | $814,896 |
| Lenalidomide | 15 | $229,374 |
| NyvepriaPegfilgrastim-Apgf | 29 | $108,923 |
| ZarxioFilgrastim-Sndz | 21 | $78,522 |
| NivestymFilgrastim-Aafi | 18 | $46,838 |
| EliquisApixaban | 13 | $9,136 |
| ValacyclovirValacyclovir Hcl | 61 | $2,616 |
| Fluconazole | 66 | $1,879 |
| Atovaquone | 12 | $1,659 |
| Acyclovir | 87 | $1,267 |
| MethotrexateMethotrexate Sodium | 15 | $580 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 83 | $513 |
| Ciprofloxacin Hcl | 52 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $10,941 | $1,733,723114 claims |
| AbbVieVenclexta | $39,752 | $814,89656 claims |
| PfizerNyvepria, Nivestym, Eliquis | $1,857 | $164,89660 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- David SiegelHackensack$171K
- Andrew IpHackensack$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.